

CITATION REPORT

List of articles citing

Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study

DOI: [10.1371/journal.pone.0237693](https://doi.org/10.1371/journal.pone.0237693)
PLoS ONE, 2020, 15, e0237693.

Source: <https://exaly.com/paper-pdf/75974487/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
99	Addition of Tocilizumab to the Standard of Care Reduces Mortality in Severe COVID-19: A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 2020 , 7, 586221	4.9	30
98	Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial. <i>International Immunopharmacology</i> , 2020 , 89, 107102	5.8	19
97	Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease. <i>International Immunopharmacology</i> , 2020 , 89, 107018	5.8	34
96	Hydroxychloroquine is effective, and consistently so when provided early, for COVID-19: a systematic review. <i>New Microbes and New Infections</i> , 2020 , 38, 100776	4.1	20
95	Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19. <i>Journal of Critical Care</i> , 2020 , 59, 176-190	4	44
94	Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials. <i>SN Comprehensive Clinical Medicine</i> , 2020 , 2, 1-12	2.7	11
93	The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics. <i>Life Sciences</i> , 2020 , 257, 118097	6.8	36
92	Chloroquine, hydroxychloroquine, and COVID-19: Systematic review and narrative synthesis of efficacy and safety. <i>Saudi Pharmaceutical Journal</i> , 2020 , 28, 1760-1776	4.4	14
91	Immunomodulation as Treatment for Severe Coronavirus Disease 2019: A Systematic Review of Current Modalities and Future Directions. <i>Clinical Infectious Diseases</i> , 2021 , 72, e1130-e1143	11.6	14
90	Frequency of Long QT in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine: A Meta-analysis. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106212	14.3	9
89	Impact of Hydroxychloroquine on Mortality in Hospitalized Patients with COVID-19: Systematic Review and Meta-Analysis. <i>Pharmacy (Basel, Switzerland)</i> , 2020 , 8,	2	4
88	A 21st Century Evil: Immunopathology and New Therapies of COVID-19. <i>Frontiers in Immunology</i> , 2020 , 11, 562264	8.4	5
87	Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis. <i>Journal of General Internal Medicine</i> , 2020 , 35, 3308-3314	4	59
86	The role of Interleukin 6 inhibitors in therapy of severe COVID-19. <i>Biomedicine and Pharmacotherapy</i> , 2020 , 131, 110698	7.5	46
85	National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1704-1716	4.5	31
84	Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review. <i>Pulmonology</i> , 2021 , 27, 52-66	3.7	69
83	Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 30-42	5.1	70

82	Cardiac Toxicity of Chloroquine or Hydroxychloroquine in Patients With COVID-19: A Systematic Review and Meta-regression Analysis. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021 , 5, 137-150	3.1	21
81	Immunomodulation for the management of severe SARS-CoV2 infections. State of the art and review of the literature. <i>Biochemical and Biophysical Research Communications</i> , 2021 , 538, 151-155	3.4	2
80	Prevalence of diabetes, management and outcomes among Covid-19 adult patients admitted in a specialized tertiary hospital in Riyadh, Saudi Arabia. <i>Diabetes Research and Clinical Practice</i> , 2021 , 172, 108538	7.4	18
79	Randomised controlled trials for COVID-19: evaluation of optimal randomisation methodologies-need for data validation of the completed trials and to improve ongoing and future randomised trial designs. <i>International Journal of Antimicrobial Agents</i> , 2021 , 57, 106222	14.3	13
78	Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. <i>Annals of Medicine</i> , 2021 , 53, 117-134	1.5	26
77	Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis. <i>BMJ Supportive and Palliative Care</i> , 2021 , 11, 45-52	2.2	22
76	Efficacy and safety of tocilizumab in the management of COVID-19: A systematic review and meta-analysis of observational studies.		
75	Hydroxychloroquine in the post-COVID-19 era: will this pandemic upset decades of clinical practice?. <i>Clinical Rheumatology</i> , 2021 , 40, 1649-1657	3.9	1
74	COVID-19 and the generation of novel scientific knowledge: Research questions and study designs. <i>Journal of Evaluation in Clinical Practice</i> , 2021 , 27, 694-707	2.5	1
73	Combination therapy of Tocilizumab and steroid for management of COVID-19 associated cytokine release syndrome: A single center experience from Pune, Western India.		
72	Optimal use of tocilizumab for severe and critical COVID-19: a systematic review and meta-analysis. <i>F1000Research</i> , 2021 , 10, 73	3.6	9
71	Biases in Evaluating the Safety and Effectiveness of Drugs for the Treatment of COVID-19: Designing Real-World Evidence Studies. <i>American Journal of Epidemiology</i> , 2021 , 190, 1452-1456	3.8	9
70	Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19. <i>Thorax</i> , 2021 , 76, 907-919	7.3	49
69	Understanding Viral Infection Mechanisms and Patient Symptoms for the Development of COVID-19 Therapeutics. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	5
68	Repurposing Quinoline and Artemisinin Antimalarials as Therapeutics for SARS-CoV-2: Rationale and Implications. <i>ACS Pharmacology and Translational Science</i> , 2021 , 4, 613-623	5.9	3
67	COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients. <i>PLoS ONE</i> , 2021 , 16, e0248128	3.7	4
66	QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 , 30, 694-706	2.6	13
65	Mortality in mechanically ventilated patients with COVID-19: a systematic review. <i>Expert Review of Medical Devices</i> , 2021 , 18, 457-471	3.5	4

64	Quinine Inhibits Infection of Human Cell Lines with SARS-CoV-2. <i>Viruses</i> , 2021 , 13,	6.2	12
63	Efficacy and safety of Tocilizumab in severe and critical COVID-19: A Systematic Review and Meta-Analysis. <i>Expert Review of Clinical Immunology</i> , 2021 , 17, 499-511	5.1	12
62	The time to offer treatments for COVID-19. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 30, 505-518	5.9	9
61	The Rise and Fall of Hydroxychloroquine with the COVID-19 Pandemic: Narrative Review of Selected Data. <i>Rheumatology and Therapy</i> , 2021 , 8, 681-691	4.4	2
60	No evidence of tocilizumab treatment efficacy for severe to critical SARS-CoV2 infected patients: Results from a retrospective controlled multicenter study. <i>Medicine (United States)</i> , 2021 , 100, e26023	1.8	2
59	Tocilizumab as treatment for COVID-19: A systematic review and meta-analysis. <i>World Journal of Methodology</i> , 2021 , 11, 95-109	1.2	1
58	Association between IL-6 and severe disease and mortality in COVID-19 disease: a systematic review and meta-analysis. <i>Postgraduate Medical Journal</i> , 2021 ,	2	8
57	Hydroxychloroquine and mortality in COVID-19 patients: a systematic review and a meta-analysis of observational studies and randomized controlled trials. <i>Pathogens and Global Health</i> , 2021 , 115, 456-466 ^{3,1}		5
56	Matched cohort study on the efficacy of tocilizumab in patients with COVID-19. <i>One Health</i> , 2021 , 12, 100214	7.6	5
55	Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database. <i>Expert Opinion on Drug Safety</i> , 2021 , 20, 1125-1136	4.1	7
54	Disease-drug and drug-drug interaction in COVID-19: Risk and assessment. <i>Biomedicine and Pharmacotherapy</i> , 2021 , 139, 111642	7.5	19
53	Efficacy and Safety of Tocilizumab Treatment COVID-19 Patients: A Case-Control Study and Meta-Analysis. <i>Infectious Diseases and Therapy</i> , 2021 , 10, 1677-1698	6.2	0
52	Development and validation of a prognostic 40-day mortality risk model among hospitalized patients with COVID-19. <i>PLoS ONE</i> , 2021 , 16, e0255228	3.7	1
51	Combination therapy of Tocilizumab and steroid for management of COVID-19 associated cytokine release syndrome: A single center experience from Pune, Western India. <i>Medicine (United States)</i> , 2021 , 100, e26705	1.8	3
50	Drug-Induced Liver Disturbance During the Treatment of COVID-19. <i>Frontiers in Pharmacology</i> , 2021 , 12, 719308	5.6	4
49	Azithromycin in patients with Covid-19; a systematic review and metanalysis.		1
48	Systematic Review and Meta-Analysis of Tocilizumab Therapy versus Standard of Care in over 15,000 COVID-19 Pneumonia Patients during the First Eight Months of the Pandemic. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	8
47	Role of toll-like receptor 7/8 pathways in regulation of interferon response and inflammatory mediators during SARS-CoV2 infection and potential therapeutic options. <i>Biomedicine and Pharmacotherapy</i> , 2021 , 141, 111794	7.5	10

46	Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study. <i>PLoS ONE</i> , 2021 , 16, e0257376	3.7	2
45	A Systematic Review and a Meta-Analysis Comparing Prophylactic and Therapeutic Low Molecular Weight Heparins for Mortality Reduction in 32,688 COVID-19 Patients. <i>Frontiers in Pharmacology</i> , 2021 , 12, 698008	5.6	4
44	Beneficial and harmful outcomes of tocilizumab in severe COVID-19: A systematic review and meta-analysis. <i>Pharmacotherapy</i> , 2021 , 41, 884-906	5.8	7
43	A Comprehensive Summary of the Knowledge on COVID-19 Treatment. 2021 , 12, 155-191		13
42	Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study. <i>BMC Infectious Diseases</i> , 2021 , 21, 72	4	19
41	Rationale for azithromycin in COVID-19: an overview of existing evidence. <i>BMJ Open Respiratory Research</i> , 2021 , 8,	5.6	23
40	The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients. <i>Internal and Emergency Medicine</i> , 2020 , 15, 1501-1506	3.7	18
39	COVID-19 and Cancer: Current Challenges and Perspectives. <i>Cancer Cell</i> , 2020 , 38, 629-646	24.3	92
38	A systematic review and meta-analysis of Anakinra, Sarilumab, Siltuximab and Tocilizumab for Covid-19.		14
37	THE TIME COURSE OF THERAPEUTIC INTERVENTIONS FOR COVID-19.		2
36	Beneficial and harmful outcomes of tocilizumab in severe COVID-19: a systematic review and meta-analysis.		3
35	Low dose hydroxychloroquine is associated with lower mortality in COVID-19: a meta-analysis of 26 studies and 44,521 patients.		2
34	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications. <i>Infection and Drug Resistance</i> , 2020 , 13, 4673-4695	4.2	20
33	Rational Drug Repurposing: Focus on Lysosomotropism, Targets in Disease Process, Drug Profile, and Pulmonary Tissue Accumulation in SARS-CoV-2 Infection/COVID-19. <i>Frontiers in Pharmacology</i> , 2020 , 11, 584881	5.6	5
32	Current Evidence of Interleukin-6 Signaling Inhibitors in Patients With COVID-19: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2020 , 11, 615972	5.6	21
31	The Role of Hydroxychloroquine in COVID-19 Treatment: A Systematic Review and Meta-Analysis. <i>Annals of the Academy of Medicine, Singapore</i> , 2020 , 49,	2.8	7
30	The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review. <i>PeerJ</i> , 2020 , 8, e10322	3.1	25
29	Azithromycin in patients with COVID-19: a systematic review and meta-analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 ,	5.1	2

28	Modulation of Covid-19 cytokine storm by tocilizumab. <i>Journal of Medical Virology</i> , 2021 ,	19.7	4
27	Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis. <i>Respirology</i> , 2021 , 26, 1027-1040	3.6	7
26	The design and analysis of non-randomized studies: a case study of off-label use of hydroxychloroquine in the COVID-19 pandemic. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 30, 111-117 ⁹	5.9	
25	COVID-19 as cause of viral sepsis: A Systematic Review and Meta-Analysis.		1
24	The Role of Hydroxychloroquine in COVID-19 Treatment: A Systematic Review and Meta-Analysis. <i>Annals of the Academy of Medicine, Singapore</i> , 2020 ,	2.8	1
23	Efficacy and safety of chloroquine and hydroxychloroquine for treatment of COVID-19 patients-a systematic review and meta-analysis of randomized controlled trials. <i>American Journal of Cardiovascular Disease</i> , 2021 , 11, 93-107	0.9	9
22	TextEssence: A Tool for Interactive Analysis of Semantic Shifts Between Corpora. 2021 , 2021, 106-115		
21	Predictors and microbiology of respiratory and bloodstream bacterial infection in patients with COVID-19: living rapid review update and meta-regression. <i>Clinical Microbiology and Infection</i> , 2021 ,	9.5	9
20	Efficacy of chloroquine and hydroxychloroquine for the treatment of hospitalized COVID-19 patients: a meta-analysis. <i>Future Virology</i> , 2021 ,	2.4	2
19	Safety profile assessment of drug products used for the pathogenetic treatment of COVID19. <i>Kliniceskaa Mikrobiologia I Antimikrobnaa Himioterapia</i> , 2021 , 23, 314-329	1.3	
18	Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy.. <i>International Journal of Biological Sciences</i> , 2022 , 18, 459-472	11.2	7
17	The Role of Cytokines and Chemokines in Severe Acute Respiratory Syndrome Coronavirus 2 Infections.. <i>Frontiers in Immunology</i> , 2022 , 13, 832394	8.4	4
16	Assessment of Recovery Time, Worsening and Death, among COVID-19 inpatients and outpatients, under treatment with Hydroxychloroquine or Chloroquine plus Azithromycin Combination in Burkina Faso.. <i>International Journal of Infectious Diseases</i> , 2022 ,	10.5	0
15	A critical analysis about the supposed role of azithromycin in the treatment of covid-19. <i>Revista Ciencias Em Saude</i> , 2021 , 11, 11-21	0.1	
14	A systematic review of real-world clinical practice data in COVID-19: non-interventional studies. <i>Farmakoekonomika</i> , 2022 , 15, 145-161	1.1	
13	Image_1.JPEG. 2020 ,		
12	Image_2.JPEG. 2020 ,		
11	Table_1.docx. 2020 ,		

10	Hydroxychloroquine and Mortality in SARS-Cov-2 Infection; The HOPE- Covid-19 Registry.. <i>Anti-Infective Agents</i> , 2022 , 20,	0.6	
9	Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review. <i>Pharmaceuticals</i> , 2022 , 15, 634	5.2	1
8	Biologics in COVID-19 So Far: Systematic Review. <i>Pharmaceuticals</i> , 2022 , 15, 783	5.2	0
7	Learning Causal Effects From Observational Data in Healthcare: A Review and Summary. <i>Frontiers in Medicine</i> , 9,	4.9	
6	Hydroxychloroquine pre-exposure prophylaxis to prevent SARS-CoV-2 among health care workers at risk for SARS-CoV-2 exposure: A nonrandomized controlled trial.		
5	Azithromycin use and outcomes in patients with COVID-19: an observational real-world study. 2022 , 124, 27-34		0
4	A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases. 2022 , 8, e002359		1
3	Antibody Therapy for COVID-19: Categories, Pros, and Cons.		0
2	Cancer Epidemiology. 1-12		0
1	Unit information prior for incorporating real-world evidence into randomized controlled trials. 2023 , 32, 229-241		0